{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:23:18Z","timestamp":1793391798302,"version":"4.5.0"},"reference-count":211,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","semarthritisrheumatism.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.semarthrit.2015.10.001","type":"journal-article","created":{"date-parts":[[2015,10,25]],"date-time":"2015-10-25T09:27:20Z","timestamp":1445765240000},"page":"519-532","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis"],"prefix":"10.1016","volume":"45","author":[{"given":"Fabrizio","family":"Cantini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Niccoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlotta","family":"Nannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Cassar\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Kaloudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ennio","family":"Giulio Favalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Becciolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Biggioggero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Benucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Li Gobbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Grossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Infantino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Meacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariangela","family":"Manfredi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Guiducci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Bellando-Randone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Matucci-Cerinic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Foti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcella","family":"Di Gangi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Mosca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Tani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Palmieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delia","family":"Goletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2015.10.001_bib1","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/acr.21641","article-title":"update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis","volume":"64","author":"Singh","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib2","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib3","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/ard.2011.151027","article-title":"update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis","volume":"70","author":"Braun","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib4","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1136\/ard.2008.094946","article-title":"Treatment recommendations for psoriatic arthritis","volume":"68","author":"Ritchlin","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib5","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3899\/jrheum.100665","article-title":"Comparison of certolizumab pegol with other anticytokine agents for treatment of rheumatoid arthritis: a multiple-treatment Bayesian metaanalysis","volume":"38","author":"Launois","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib6","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1503\/cmaj.091391","article-title":"A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview","author":"Singh","year":"2009","journal-title":"CMAJ"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib7","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1136\/ard.2010.132134","article-title":"Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis","volume":"70","author":"Salliot","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib8","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.semarthrit.2009.12.002","article-title":"Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs","volume":"39","author":"Bergman","year":"2010","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib9","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1093\/rheumatology\/ket266","article-title":"Impact of biologic therapy on functional status in patients with rheumatoid arthritis\u2014a meta-analysis","volume":"52","author":"Callhoff","year":"2013","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib10","first-page":"333","article-title":"Efficacy of biologic agents in improving the Health Assessment Questionnaire (HAQ) score in established and early rheumatoid arthritis: a meta-analysis with indirect comparisons","volume":"32","author":"Barra","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib11","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jbspin.2012.09.023","article-title":"Meta-analysis of clinical and radiological efficacy of biologics in rheumatoid arthritis patients naive or inadequately responsive to methotrexate","volume":"80","author":"Pierreisnard","year":"2013","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib12","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.semarthrit.2013.11.006","article-title":"The comparison of effects of biologic agents on rheumatoid arthritis damage progression is biased by period of enrollment: data from a systematic review and meta-analysis","volume":"43","author":"Favalli","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib13","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1136\/ard.2007.080002","article-title":"Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate","volume":"67","author":"Schiff","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib14","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1136\/annrheumdis-2013-203843","article-title":"Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial","volume":"73","author":"Schiff","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib15","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/annrheumdis-2012-203090","article-title":"A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study","volume":"72","author":"Yoo","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib16","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.20217","volume":"50","author":"Keystone","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib17","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1056\/NEJM199901283400401","article-title":"A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate","volume":"340","author":"Weinblatt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib19","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1002\/art.23964","article-title":"Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study","volume":"58","author":"Keystone","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib20","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1136\/ard.2009.116319","article-title":"Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study","volume":"69","author":"Keystone","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib21","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","article-title":"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial","volume":"371","author":"Smolen","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib22","doi-asserted-by":"crossref","first-page":"865","DOI":"10.7326\/0003-4819-144-12-200606200-00003","article-title":"Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial","volume":"144","author":"Kremer","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib23","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/art.10141","article-title":"Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial","volume":"46","author":"Cohen","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib24","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1136\/annrheumdis-2013-204632","article-title":"Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial","volume":"74","author":"Smolen","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib25","doi-asserted-by":"crossref","first-page":"522","DOI":"10.3899\/jrheum.080663","article-title":"Patients with moderate rheumatoid arthritis (RA) achieve better disease activity states with etanercept treatment than patients with severe RA","volume":"36","author":"Keystone","year":"2009","journal-title":"J Rheumatol"},{"issue":"Suppl 10","key":"10.1016\/j.semarthrit.2015.10.001_bib26","first-page":"S2233","article-title":"Comparative effectiveness and time to response among abatacept, adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in a real world routine care registry [Abstract]","volume":"63","author":"Yazici","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib27","first-page":"2433","article-title":"Retention rates of tumor necrosis factor blockers in daily practice in 770 rheumatic patients","volume":"33","author":"Duclos","year":"2006","journal-title":"J Rheumatol"},{"issue":"Suppl 2","key":"10.1016\/j.semarthrit.2015.10.001_bib28","article-title":"Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis","volume":"62","author":"Flendrie","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib29","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.3899\/jrheum.101142","article-title":"Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry","volume":"38","author":"Markenson","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib30","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1136\/annrheumdis-2011-150573","article-title":"A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry","volume":"71","author":"Greenberg","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib31","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/S0149-2918(08)80063-X","article-title":"Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis","volume":"30","author":"Tang","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib32","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/art.24463","article-title":"Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis","volume":"61","author":"Pan","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib33","first-page":"857","article-title":"Drug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and seronegative spondyloarthritis: analysis from the MonitorNet database","volume":"31","author":"Scir\u00e8","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib34","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.semarthrit.2013.07.011","article-title":"Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: low rates of remission and 5-year drug survival","volume":"43","author":"Flouri","year":"2013","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib35","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/j.1749-6632.2009.04621.x","article-title":"TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice","volume":"1173","author":"Marchesoni","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib36","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/art.27227","volume":"62","author":"Hetland","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib37","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.3899\/jrheum.111125","article-title":"Longterm retention of tumor necrosis factor-\u03b1 inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors","volume":"39","author":"Iannone","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib38","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1136\/annrheumdis-2013-204128","article-title":"Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab","volume":"74","author":"Neovius","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib39","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jbspin.2014.02.014","article-title":"Retention rates of adalimumab, etanercept and infliximab as first and second-line biotherapy in patients with rheumatoid arthritis in daily practice","volume":"81","author":"Frazier-Mironer","year":"2014","journal-title":"Joint Bone Spine"},{"issue":"Suppl 10","key":"10.1016\/j.semarthrit.2015.10.001_bib40","first-page":"S1038","article-title":"The 12-years retention rate of the first-line TNF-inhibitor in the treatment of rheumatoid arthritis: real-life data from a local registry [abstract]","volume":"66","author":"Favalli","year":"2014","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib41","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1136\/ard.2010.140129","article-title":"Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry","volume":"70","author":"Leffers","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib42","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1007\/s10067-013-2303-6","article-title":"Abatacept and its use in the treatment of rheumatoid arthritis (RA) in the Czech Republic-data from the ATTRA registry","volume":"32","author":"Hor\u00e1k","year":"2013","journal-title":"Clin Rheumatol"},{"issue":"Suppl 10","key":"10.1016\/j.semarthrit.2015.10.001_bib43","first-page":"S1794","article-title":"Comparable persistency and effectiveness of abatacept versus anti-TNF agents in the treatment of biologic-na\u00efve rheumatoid arthritis patients using the CORRONA Registry [abstract]","volume":"62","author":"Harrold","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib44","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1093\/rheumatology\/ker295","article-title":"An observational study of tocilizumab and TNF-\u03b1 inhibitor use in a Japanese community hospital: different remission rates, similar drug survival and safety","volume":"50","author":"Yoshida","year":"2011","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib45","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1590\/S1679-45082013000400015","article-title":"Retention rates of infliximab and tocilizumab during a 3-year period in a Brazilian hospital","volume":"11","author":"Golmia","year":"2013","journal-title":"Einstein"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib46","article-title":"Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study","author":"Gabay","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib47","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.3899\/jrheum.140876","article-title":"Drug therapies for peripheral joint disease in psoriatic arthritis: a systematic review","volume":"41","author":"Acosta Felquer","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta11280","article-title":"Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation","volume":"11","author":"McLeod","year":"2007","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib49","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3111\/13696998.2012.660255","article-title":"Indirect comparison of the effects of anti-TNF biological agents in patients with ankylosing spondylitis by means of a mixed treatment comparison performed on efficacy data from published randomised, controlled trials","volume":"15","author":"Migliore","year":"2012","journal-title":"J Med Econ"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib50","first-page":"717","article-title":"Indirect comparison of anti-TNF-\u03b1 agents for active ankylosing spondylitis: mixed treatment comparison of randomized controlled trials","volume":"31","author":"Shu","year":"2013","journal-title":"Clin Exp Rheumatol"},{"issue":"Suppl 1","key":"10.1016\/j.semarthrit.2015.10.001_bib51","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1007\/s10198-014-0593-5","article-title":"Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis","volume":"15","author":"Baji","year":"2014","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib52","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s40261-014-0246-6","article-title":"Indirect comparison between subcutaneous biologic agents in ankylosing spondylitis","volume":"35","author":"Migliore","year":"2015","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib53","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","article-title":"Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study","volume":"73","author":"Landew\u00e9","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib54","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1136\/annrheumdis-2013-204575","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"73","author":"Ramiro","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib55","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1517\/14740338.2014.851666","article-title":"Drug safety evaluation of certolizumab pegol","volume":"13","author":"Ferrante","year":"2014","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib56","first-page":"926836","article-title":"HBV reactivation in patients treated with antitumor necrosis factor-alpha (TNF-\u03b1) agents for rheumatic and dermatologic conditions: a systematic review and meta-analysis","author":"Cantini","year":"2014","journal-title":"Int J Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib57","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.autrev.2015.01.011","article-title":"Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice","volume":"14","author":"Cantini","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib58","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/rheumatology\/keq242","volume":"50","author":"Galloway","year":"2011","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib59","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/rheumatology\/kep146","article-title":"Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice","volume":"48","author":"Elewaut","year":"2009","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib60","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.autrev.2014.04.003","article-title":"Italian Expert Panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease","volume":"13","author":"Olivieri","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib61","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/annrheumdis-2013-203582","article-title":"Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis","volume":"74","author":"Stolwijk","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib62","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1756-185X.2010.01540.x","article-title":"Psoriatic arthritis: a systematic review","volume":"13","author":"Cantini","year":"2010","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib63","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"Ritchlin","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib64","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/rheumatology\/keu237","article-title":"Psoriatic arthritis: current therapy and future approaches","volume":"54","author":"Huynh","year":"2015","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib65","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.3899\/jrheum.140879","article-title":"GRAPPA Dactylitis Study Group. Comprehensive treatment of dactylitis in psoriatic arthritis","volume":"41","author":"Rose","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib66","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1517\/14712598.2014.890587","article-title":"Ustekinumab: targeting the IL-17 pathway to improve outcomes in psoriatic arthritis","volume":"14","author":"Weitz","year":"2014","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib67","article-title":"On the HUNT for cardiovascular risk factors and disease in patients with psoriatic arthritis: population-based data from the Nord-Tr\u00f8ndelag Health Study","author":"Gulati","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib68","doi-asserted-by":"crossref","DOI":"10.1002\/acr.22536","article-title":"Cardiovascular risk profile at the onset of psoriatic arthritis: a population-based, cohort study","author":"Ernste","year":"2015","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib69","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","article-title":"The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis","volume":"74","author":"Roubille","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.semarthrit.2015.10.001_bib70","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD008794.pub2","article-title":"Adverse effects of biologics: a network meta-analysis and Cochrane overview","volume":"16","author":"Singh","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib71","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2217\/imt.13.10","article-title":"Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature","volume":"5","author":"Jain","year":"2013","journal-title":"Immunotherapy"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib72","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1136\/ard.61.11.994","article-title":"Mortality risk associated with rheumatoid arthritis in a prospective cohort of older women: results from the Iowa Women\u2019s Health Study","volume":"61","author":"Mikuls","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib73","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/art.1780140119","article-title":"Infections in rheumatoid arthritis","volume":"14","author":"Baum","year":"1971","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib74","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.autrev.2012.06.008","article-title":"Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept andinfliximab in the GISEA registry","volume":"12","author":"Atzeni","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib75","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3109\/s10165-011-0488-6","article-title":"Incidence of serious respiratory infections in patients with rheumatoid arthritis treated with tocilizumab","volume":"22","author":"Hoshi","year":"2012","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib76","first-page":"243","article-title":"Ustekinumab for the treatment of psoriatic arthritis: an update","volume":"7","author":"Davari","year":"2014","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"Suppl 6","key":"10.1016\/j.semarthrit.2015.10.001_bib77","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kes283","article-title":"Overview of safety of non-biologic and biologic DMARDs","volume":"51","author":"Ruderman","year":"2012","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib78","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1046\/j.1365-2249.1999.00812.x","article-title":"HBV-specific immune defect in chronic hepatitis B (CHB) is correlated with a dysregulation of pro-and anti-inflammatory cytokines","volume":"115","author":"Schlaak","year":"1999","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib79","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1136\/annrheumdis-2014-206711","article-title":"A comparison of safety profiles of tumour necrosis factor \u03b1 inhibitors and rituximab therapy in patients with rheumatoid arthritis and chronic hepatitis C","volume":"74","author":"Chen","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib80","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/jama.2009.146","article-title":"Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents","volume":"301","author":"Strangfeld","year":"2009","journal-title":"J Am Med Assoc"},{"issue":"309","key":"10.1016\/j.semarthrit.2015.10.001_bib81","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1001\/jama.2013.1099","article-title":"Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster","volume":"6","author":"Winthrop","year":"2013","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib82","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/rmv.655","article-title":"Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection","volume":"20","author":"Cannon","year":"2010","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib83","doi-asserted-by":"crossref","first-page":"R142","DOI":"10.1186\/ar3083","article-title":"Maintenance of cytomegalovirus-specific CD4pos T-cell response in rheumatoid arthritis patients receiving anti-tumor necrosis factor treatments","volume":"12","author":"Davignon","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib84","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.3899\/jrheum.081270","article-title":"A followup study of asymptomatic carriers of Pneumocystis jiroveci during immunosuppressive therapy for rheumatoid arthritis","volume":"36","author":"Mori","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib85","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1136\/annrheumdis-2013-203407","article-title":"Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study","volume":"73","author":"Baddley","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib86","doi-asserted-by":"crossref","first-page":"R66","DOI":"10.1186\/ar1933","article-title":"Clinical and functional remission: even through biologics are superior to conventional DMARDs overall success rates remain low-results from RABBIT, the German biologics register","volume":"8","author":"Listing","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib87","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/art.23333","article-title":"The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study","volume":"59","author":"Heiberg","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib88","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1136\/ard.2010.139774","article-title":"Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register","volume":"70","author":"Soliman","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib89","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1477-7525-12-102","article-title":"Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs\u2014a systematic review and network meta-analysis","volume":"12","author":"Jansen","year":"2014","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib90","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1056\/NEJM200011303432201","article-title":"A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis","volume":"343","author":"Bathon","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib91","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1002\/art.10308","article-title":"Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes","volume":"46","author":"Genovese","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib92","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(04)15640-7","article-title":"Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial","volume":"363","author":"Klareskog","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib93","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/art.21655","article-title":"Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial","volume":"54","author":"van der Heijde","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib94","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","volume":"54","author":"Breedveld","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib95","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1136\/annrheumdis-2012-201796","volume":"1","author":"Takeuchi","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib96","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1136\/ard.2008.099291","article-title":"Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease modifying antirheumatic therapy: the FAST4WARD study","volume":"68","author":"Fleischmann","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 5","key":"10.1016\/j.semarthrit.2015.10.001_bib97","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kes116","article-title":"Biologic monotherapy as initial treatment in patients with early rheumatoid arthritis","volume":"51","author":"G\u00f3mez-Reino","year":"2012","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib98","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/ard.2008.105197","article-title":"Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study","volume":"69","author":"Jones","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib99","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(13)60250-0","article-title":"Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial","volume":"381","author":"Gabay","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib100","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1136\/annrheumdis-2013-204761","article-title":"Clinical, radiographic and immunogenic effectsafter 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study","volume":"73","author":"Dougados","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib101","doi-asserted-by":"crossref","first-page":"409","DOI":"10.18553\/jmcp.2015.21.5.409","article-title":"Comparative Efficacy of Novel DMARDs as monotherapy andin combination with methotrexate in rheumatoidarthritis patients with inadequate response to conventional DMARDs: network meta-analysis","volume":"21","author":"Buckley","year":"2015","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib102","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1136\/ard.2006.060608","article-title":"High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis","volume":"66","author":"Bobbio-Pallavicini","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib103","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1136\/ard.2004.023523","article-title":"Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis","volume":"64","author":"De Rycke","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib104","doi-asserted-by":"crossref","first-page":"e89442","DOI":"10.1371\/journal.pone.0089442","article-title":"The status of rheumatoid factor and anti-cyclic citrullinated peptide antibody are not associated with the effect of anti-TNFalpha agent treatment in patients with rheumatoid arthritis: a meta-analysis","volume":"9","author":"Lv","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib105","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1136\/ard.2005.038851","article-title":"The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis","volume":"65","author":"Chen","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib106","doi-asserted-by":"crossref","first-page":"R3","DOI":"10.1186\/ar1851","article-title":"Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study","volume":"8","author":"Atzeni","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib107","first-page":"1972","article-title":"Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis","volume":"35","author":"Bos","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib108","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.semarthrit.2012.11.007","article-title":"Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: Systematic review and meta-analysis","volume":"43","author":"Maneiro","year":"2013","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib109","doi-asserted-by":"crossref","first-page":"370","DOI":"10.3109\/s10165-010-0409-0","article-title":"In rheumatoid arthritis patients treated with tocilizumab, the rate of clinical disease activity index (CDAI) remission at 24 weeks is superior in those with higher titers of IgM-rheumatoid factor at baseline","volume":"21","author":"Kawashiri","year":"2011","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib110","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1093\/rheumatology\/kep314","article-title":"Rheumatoid factor positivity rather than anti-CCP positivity, a lower dis-ability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis","volume":"48","author":"Quartuccio","year":"2009","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib111","doi-asserted-by":"crossref","first-page":"e40362","DOI":"10.1371\/journal.pone.0040362","article-title":"Biomarkers of good EULAR response to the B cell depletion therapy in all seropositive rheumatoid arthritis patients: clues for the pathogenesis","volume":"7","author":"Ferraccioli","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib112","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1136\/annrheumdis-2011-201109","article-title":"Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the \u2018Orencia and Rheumatoid Arthritis\u2019 registry","volume":"71","author":"Gottenberg","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib113","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/annrheumdis-2013-203923","article-title":"MRP8\/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis","volume":"74","author":"Choi","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib114","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3899\/jrheum.140628","article-title":"Calprotectin as a biomarker for rheumatoid arthritis: a systematic review","volume":"42","author":"Abildtrup","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib115","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1136\/ard.2009.126441","article-title":"Decrease in immunoglobulin free light chains in patients with rheumatoid arthritis upon rituximab (anti-CD20) treatment correlates with decrease in disease activity","volume":"69","author":"Kormelink","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib116","doi-asserted-by":"crossref","first-page":"666","DOI":"10.3899\/jrheum.130905","article-title":"Abatacept reduces levels of switched memory B cells, autoantibodies, and immunoglobulins in patients with rheumatoid arthritis","volume":"41","author":"Scarsi","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib117","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1136\/annrheumdis-2011-200108","article-title":"Treating to target matrix metalloproteinase 3 normalisation together with disease activity score below 2.6 yields better effects than each alone in rheumatoid arthritis patients: T-4 Study","volume":"71","author":"Urata","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib118","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/1471-2474-14-229","article-title":"Early increase in serum-COMP is associated with joint damage progression over the first five years in patients with rheumatoid arthritis","volume":"14","author":"Andersson","year":"2013","journal-title":"BMC Musculoskel Dis"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib119","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2174\/1573397111666150113215950","article-title":"Can tocilizumab decrease cartilage oligomeric matrix protein levels and disease activity in patients with long-standing rheumatoid arthritis?","volume":"10","author":"Benucci","year":"2015","journal-title":"Curr Rheumatol Rev"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib120","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3899\/jrheum.140223","article-title":"Serum soluble bone turnover biomarkers in psoriatic arthritis and psoriatic spondyloarthropathy","volume":"42","author":"Jadon","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib121","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/art.24092","article-title":"Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies","volume":"59","author":"Avi\u00f1a-Zubieta","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib122","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1136\/ard.2009.113696","article-title":"EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis","volume":"69","author":"Peters","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib123","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.amjmed.2013.08.013","article-title":"Cardiovascular risk and psoriasis: beyond the traditional risk factors","volume":"127","author":"Coumbe","year":"2014","journal-title":"Am J Med"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib124","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.semarthrit.2014.12.002","article-title":"Cardiovascular morbidity and associated risk factors in Spanish patients with chronic inflammatory rheumatic diseases attending rheumatology clinics: Baseline data of the CARMA Project","volume":"44","author":"Casta\u00f1eda","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib125","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jbspin.2010.07.016","article-title":"Traditional cardiovascular risk factors in rheumatoid arthritis: a meta-analysis","volume":"78","author":"Boyer","year":"2011","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib126","doi-asserted-by":"crossref","first-page":"e0117952","DOI":"10.1371\/journal.pone.0117952","article-title":"The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"10","author":"Baghdadi","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib127","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1002\/art.21204","article-title":"Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort","volume":"52","author":"Goodson","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib128","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/acr.20371","article-title":"Systematic review and meta-analysis: anti-tumor necrosis factor \u03b1 therapy and cardiovascular events in rheumatoid arthritis","volume":"63","author":"Barnabe","year":"2011","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib129","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1093\/rheumatology\/keq316","article-title":"Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review","volume":"50","author":"Westlake","year":"2011","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib130","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2013.02.016","article-title":"Cardiovascular risk in rheumatoid arthritis: comparing TNF-\u03b1 blockade with nonbiologic DMARDs","volume":"126","author":"Solomon","year":"2013","journal-title":"Am J Med"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib131","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/annrheumdis-2013-203934","article-title":"Tumour necrosis factor blocking agents and progression of subclinical atherosclerosis in patients with ankylosing spondylitis","volume":"74","author":"van Sijl","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib132","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/RHU.0000000000000053","article-title":"Effect of golimumab on carotid atherosclerotic disease measures and cardiovascular events in inflammatory arthritides","volume":"20","author":"Wasko","year":"2014","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib133","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1136\/ard.2010.135871","article-title":"Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease","volume":"70","author":"Myasoedova","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib134","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.semarthrit.2011.04.003","article-title":"The effect of TNF-alpha blocking therapy on lipid levels in rheumatoid arthritis: a meta-analysis","volume":"41","author":"van Sijl","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib135","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1136\/annrheumdis-2011-201148","article-title":"Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis","volume":"71","author":"Da\u00efen","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib136","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1001\/jama.2011.884","article-title":"Can treatment of chronic inflammatory diseases reduce the risk of diabetes mellitus?","volume":"305","author":"Bongartz","year":"2011","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib137","first-page":"355","article-title":"Long-term anti-tumor necrosis factor-alpha treatment in patients with refractory rheumatoid arthritis: relationship between insulin resistance and disease activity","volume":"35","author":"Seriolo","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib138","doi-asserted-by":"crossref","first-page":"R141","DOI":"10.1186\/ar3874","article-title":"Anti-tumor necrosis factor therapy improves insulin resistance, beta cell function and insulin signaling in active rheumatoid arthritis patients with high insulin resistance","volume":"14","author":"Stagakis","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib139","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/acr.20657","article-title":"Diabetes mellitus risk in rheumatoid arthritis: reduced incidence with anti-tumor necrosis factor \u03b1 therapy","volume":"64","author":"Antohe","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib140","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1001\/jama.2011.878","article-title":"Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis","volume":"305","author":"Solomon","year":"2011","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib141","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1001\/archinte.166.8.902","article-title":"Effects of etanercept in patients with the metabolic syndrome","volume":"166","author":"Bernstein","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib142","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.biologicals.2010.05.003","article-title":"Effects of anti-TNF therapy on glucose metabolism in patients with ankylosing spondylitis, psoriatic arthritis or juvenile idiopathic arthritis","volume":"38","author":"da Silva","year":"2010","journal-title":"Biologicals"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib143","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13075-015-0559-8","article-title":"Significant effects of biologic therapy on lipid profiles and insulin resistance in patients with rheumatoid arthritis","volume":"17","author":"Chen","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib144","doi-asserted-by":"crossref","first-page":"e731","DOI":"10.1097\/MD.0000000000000731","article-title":"Association between anti-TNF therapy for rheumatoid arthritis and hypertension: a meta-analysis of randomized controlled trials","volume":"94","author":"Zhao","year":"2015","journal-title":"Medicine"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib145","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrrheum.2013.91","article-title":"Changes lipid levels with inflammation and therapy in RA: a maturing paradigm","volume":"9","author":"Robertson","year":"2013","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib146","doi-asserted-by":"crossref","first-page":"R141","DOI":"10.1186\/ar3455","article-title":"Integrated safety in tocilizumab clinical trials","volume":"13","author":"Schiff","year":"2011","journal-title":"Arthritis Res Ther"},{"issue":"Suppl 3","key":"10.1016\/j.semarthrit.2015.10.001_bib147","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/annrheumdis-2013-eular.1259","article-title":"Insulin resistance is improved by tocilizumab therapy in rheumatoid arthritis: results from the TOWARD study","volume":"72","author":"Mirjafari","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib148","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1002\/jps.23057","article-title":"Interleukin-1 receptor antagonist: a new therapy for type 2 diabetes mellitus","volume":"101","author":"Akash","year":"2012","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib149","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ahj.2011.06.012","article-title":"Interleukin-1\u03b2 inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)","volume":"162","author":"Ridker","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib150","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jaad.2013.09.020","article-title":"From the Medical Board of the National Psoriasis Foundation: the risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies","volume":"70","author":"Hugh","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib151","doi-asserted-by":"crossref","first-page":"e0130709","DOI":"10.1371\/journal.pone.0130709","article-title":"The impact of newer biological disease modifying anti-rheumatic drugs on cardiovascular risk factors: a 12-month longitudinal study in rheumatoid arthritis patients treated with rituximab, abatacept and tocilizumab","volume":"10","author":"Provan","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib152","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/ajg.2008.71","article-title":"Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy","volume":"104","author":"Kane","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib153","first-page":"985646","article-title":"IgG placental transfer in healthy and pathological pregnancies","author":"Palmeira","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib154","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1136\/ard.2008.105924","article-title":"Etanercept during pregnancy and lactation in a patient with rheumatoid arthritis: drug levels in maternal serum, cord blood, breast milk and the infant\u2019s serum","volume":"68","author":"Murashima","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib155","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.3899\/jrheum.100077","article-title":"Measuring multiple etanercept levels in the breast milk of a nursing mother with rheumatoid arthritis","volume":"37","author":"Keeling","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib156","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cgh.2012.11.011","article-title":"Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease","volume":"11","author":"Mahadevan","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib157","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/1741-7015-11-174","article-title":"Safety of TNF-alpha inhibitors during IBD pregnancy: a systematic review","volume":"11","author":"Nielsen","year":"2013","journal-title":"BMC Med"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib158","doi-asserted-by":"crossref","DOI":"10.1111\/bcp.12642","article-title":"Pregnancy outcome after TNF-\u03b1 inhibitor therapy during the first trimester: a prospective multicentre cohort study","author":"Weber-Schoendorfer","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib159","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.reprotox.2013.11.004","article-title":"Pregnancy outcome following gestational exposure to TNF-alpha-inhibitors: a prospective, comparative, observational study","volume":"43","author":"Diav-Citrin","year":"2014","journal-title":"Reprod Toxicol"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib160","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/ajg.2010.464","article-title":"The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn\u2019s and Colitis Organisation: pregnancy and pediatrics","volume":"106","author":"Mahadevan","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib161","first-page":"1426","article-title":"The effects of rituximab treatment during pregnancy on a neonate","volume":"91","author":"Friedrichs","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib162","first-page":"271363","article-title":"Rituximab administration in third trimester of pregnancy suppresses neonatal B cell development","author":"Klink","year":"2008","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib163","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1182\/blood-2010-07-295444","article-title":"Pregnancy outcomes after maternal exposure to rituximab","volume":"117","author":"Chakravarty","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib164","first-page":"559","article-title":"Adherence to biologic therapies and associated factors in rheumatoid arthritis, spondyloarthritis and psoriatic arthritis: a systematic literature review","author":"Lopez-Gonzalez","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib165","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinthera.2014.10.022","article-title":"Medication adherence and attrition to biologic treatment in rheumatoid arthritis patients","volume":"37","author":"Chu","year":"2015","journal-title":"Clin Ther"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib166","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2147\/CEOR.S66338","article-title":"Adherence and resource use among patients treated with biologic drugs: findings from BEETLE study","volume":"6","author":"Degli Esposti","year":"2014","journal-title":"Clinicoecon Outcomes Res"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib167","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2147\/PPA.S70834","article-title":"Reasons for discontinuation of subcutaneous biologic therapy in the treatment of rheumatoid arthritis: a patient perspective","volume":"9","author":"Bolge","year":"2015","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib168","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.3748\/wjg.v19.i27.4344","article-title":"Low rates of adherence for tumor necrosis factor-\u03b1 inhibitors in Crohn\u2019s disease and rheumatoid arthritis: results of a systematic review","volume":"19","author":"Fidder","year":"2013","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib169","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1093\/rheumatology\/keu358","article-title":"BRAGGSS. Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort","volume":"54","author":"Bluett","year":"2015","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib170","first-page":"589","article-title":"Drug adherence to biologic DMARDS with a special emphasis on the benefits of subcutaneous abatacept","volume":"6","author":"Malaviya","year":"2012","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib171","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/msc.110","article-title":"Treatment choices, preferences and decision-making by patients with rheumatoid arthritis","volume":"6","author":"Chilton","year":"2008","journal-title":"Musculoskeletal Care"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib172","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1136\/ard.2006.068296","article-title":"Patient preferences for treatment: report from a randomised comparison of treatment strategies in early rheumatoid arthritis (BeSt trial)","volume":"66","author":"Goekoop-Ruiterman","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib173","first-page":"71","article-title":"Considering patient preferences when selecting anti-tumor necrosis factor therapeutic options","volume":"7","author":"Sylwestrzak","year":"2014","journal-title":"Am Health Drug Benefits"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib174","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/acr.21768","article-title":"Obesity and reduction of the response rate to anti-tumor necrosis factor \u03b1 in rheumatoid arthritis: an approach to a personalized medicine","volume":"65","author":"Gremese","year":"2013","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib175","first-page":"1062","article-title":"Impact of obesity on 1 year outcomes: results from the METEOR Foundation International Rheumatoid Arthritis Cohort","volume":"66","author":"Sparks","year":"2014","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib176","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1136\/ard.2009.126714","article-title":"Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis","volume":"69","author":"Schoels","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib177","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.berh.2012.07.012","article-title":"The issue of comparators in economic evaluations of biologic response modifiers in rheumatoid arthritis","volume":"26","author":"Tsao","year":"2012","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib178","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/acr.20338","article-title":"Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review","volume":"63","author":"Van der Velde","year":"2011","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib179","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.2165\/00019053-200624120-00006","article-title":"Cost effectiveness of tumour necrosis factor-\u03b1 inhibitors as first-line agents in rheumatoid arthritis","volume":"24","author":"Spalding","year":"2006","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib180","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3899\/jrheum.080257","article-title":"Cost-effectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis","volume":"36","author":"Davies","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib181","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta10420","article-title":"A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness","volume":"10","author":"Chen","year":"2006","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib182","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1017\/S0266462311000195","article-title":"Cost-effectiveness of etanercept treatment in early active rheumatoid arthritis followed by dose adjustment","volume":"27","author":"Kobelt","year":"2011","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib183","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/art.24169","article-title":"Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis","volume":"61","author":"Van Den Hout","year":"2009","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib184","doi-asserted-by":"crossref","first-page":"612","DOI":"10.7326\/0003-4819-151-9-200911030-00006","article-title":"Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis","volume":"151","author":"Finckh","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib185","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/rheumatology\/ker084","article-title":"Treatment strategies aiming at remission in early rheumatoid arthritis patients: Starting with methotrexate monotherapy is cost-effective","volume":"50","author":"Schipper","year":"2011","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib186","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/rheumatology\/kem115","article-title":"Modelling the cost effectiveness of TNF-\u03b1 antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry","volume":"46","author":"Brennan","year":"2007","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib187","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/rheumatology\/ken007","article-title":"Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate","volume":"47","author":"Vera-Llonch","year":"2008","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib188","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S0002-9343(02)01243-3","article-title":"Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis","volume":"113","author":"Wong","year":"2002","journal-title":"Am J Med"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib189","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1136\/ard.2004.027565","article-title":"Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden","volume":"64","author":"Bansback","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib190","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1093\/rheumatology\/keg451","article-title":"Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK","volume":"43","author":"Brennan","year":"2004","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib191","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/rheumatology\/keg107","article-title":"The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study","volume":"42","author":"Kobelt","year":"2003","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib192","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta6210","article-title":"The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: A systematic review and economic evaluation","volume":"6","author":"Jobanputra","year":"2002","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib193","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta8110","article-title":"The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis","volume":"8","author":"Barton","year":"2004","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib194","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3111\/13696998.2011.649327","article-title":"Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis","volume":"15","author":"Soini","year":"2012","journal-title":"J Med Econ"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib195","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2165\/11594990-000000000-00000","article-title":"Cost utility of tumour necrosis factor\u2014a inhibitors for rheumatoid arthritis","volume":"30","author":"Nguyen","year":"2012","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib196","doi-asserted-by":"crossref","first-page":"576","DOI":"10.3111\/13696998.2012.665110","article-title":"Economic evaluation of tocilizumab combination in the treatment of moderate-to-severe rheumatoid arthritis in Italy","volume":"15","author":"Diamantopoulos","year":"2012","journal-title":"J Med Econ"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib197","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta8180","article-title":"The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis","volume":"8","author":"Clark","year":"2004","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib198","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s10198-012-0431-6","article-title":"The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice","volume":"14","author":"Lekander","year":"2013","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib199","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1185\/03007990802321683","article-title":"UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug","volume":"24","author":"Kielhorn","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib200","first-page":"SR1","article-title":"Challenges in economic evaluation of new drugs: experience with rituximab in Hungary","volume":"16","author":"Brodszky","year":"2010","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib201","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3111\/13696990903508021","article-title":"Indirect cost-effectiveness analyses of abatacept and rituximab in patients with moderate-to-severe rheumatoid arthritis in the United States","volume":"13","author":"Yuan","year":"2010","journal-title":"J Med Econ"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib202","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta15140","article-title":"Adalimumab, etanercept, infiximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: A systematic review and economic evaluation","volume":"15","author":"Malottki","year":"2011","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib203","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/rheumatology\/kep425","article-title":"Cost-utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting","volume":"49","author":"Hallinen","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib204","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1586\/14737167.4.3.307","article-title":"Cost-effectiveness analysis of biological treatments for rheumatoid arthritis","volume":"4","author":"Chiou","year":"2004","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib205","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/art.23374","article-title":"Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis","volume":"58","author":"Wailoo","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib206","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-2474-15-26","article-title":"Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritis","volume":"15","author":"Cawson","year":"2014","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib207","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.3111\/13696998.2013.820192","article-title":"Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis","volume":"16","author":"Bonafede","year":"2013","journal-title":"J Med Econ"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib208","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1093\/rheumatology\/keq222","article-title":"Cost-effectiveness of etanercept in patients with severe ankylosing spondylitis in Germany","volume":"49","author":"Neilson","year":"2010","journal-title":"Rheumatology"},{"issue":"Suppl 1","key":"10.1016\/j.semarthrit.2015.10.001_bib209","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1007\/s10198-014-0595-3","article-title":"Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries","volume":"15","author":"Brodszky","year":"2014","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.semarthrit.2015.10.001_bib210","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semarthrit.2015.10.001_bib211","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017215002413?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017215002413?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T19:05:50Z","timestamp":1567278350000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017215002413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":211,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S0049017215002413"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2015.10.001","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2015.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}